Mercazolil

Quick links to important sections

Mercazolil

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mercazolil

Property Description
Active ingredient Thiamazole (also known as Methimazole)
Form Oral tablet
Pharmacological class Antithyroid drug, Thioamide derivative
Common use Management of hyperthyroidism
Origin Synthetic compound

What Type of Medicine is Mercazolil?

Mercazolil is a prescription-only medication whose active component is the synthetic compound Thiamazole, internationally identified as Methimazole. It is classified as an Antithyroid drug, specifically belonging to the Thioamide derivative class of pharmaceuticals. The medication is delivered as a single-ingredient, fixed-dose oral tablet. This chemical classification is clinically recognized for its direct action on thyroid hormone production, making it a foundational treatment.

Understanding the General Purpose of Mercazolil

The primary objective of using Mercazolil is to modulate and reduce the elevated output from the thyroid gland, functioning as a thyrostatic agent. This systemic action is designed to stabilize the body’s accelerated metabolic state, providing a crucial management option for patients experiencing hyperthyroidism. Pharmacological studies have supported that this medication is often considered the preferred initial oral therapy for chemically controlling thyroid overactivity. Its general role is to provide non-surgical, long-term chemical control over the thyroid gland's function.

Composition and Chemical Origin (Thiamazole)

The core component of Mercazolil is Thiamazole, an active ingredient deemed an essential medicine, underscoring its therapeutic significance. The compound's synthetic origin ensures high purity and batch consistency, which is critical for endocrine treatments. When administered via the oral route, the standardized tablet formulation ensures reliable systemic absorption of the Thiamazole, enabling its widespread use across adult and appropriate pediatric patient groups requiring metabolic stabilization.

Regulatory References

  1. NIH StatPearls
  2. World Health Organization
  3. WHO Model List of Essential Medicines

What side effects are possible with Mercazolil?

Possible Side Effects and Safety Information

Mercazolil's (Thiamazole/Methimazole) official safety profile is primarily structured around distinguishing between common, generally minor adverse reactions and low-frequency but serious, major adverse reactions documented in regulatory documents like the FDA and EMA prescribing information. Adverse reactions are grouped by the affected System-Organ Class (SOC).


Documented Adverse Reaction Categories

Classification Examples of Reactions
Common Reactions Skin rash, urticaria (hives), itching (pruritus), nausea, vomiting, epigastric distress, arthralgia (joint pain), and myalgia (muscle pain).
Serious Reactions (Rare) Agranulocytosis, acute liver failure, aplastic anemia, and ANCA-positive vasculitis.

Key Safety Considerations

The most serious documented concerns involve the Blood and Lymphatic System Disorders (myelosuppression leading to agranulocytosis) and Hepatobiliary Disorders (potentially fatal acute liver failure). Agranulocytosis typically, though not exclusively, occurs within the initial three months of treatment. Liver function should be monitored upon suspicion of hepatic dysfunction.

Regulatory documents highlight population-specific safety considerations for pregnant individuals. Exposure, particularly during the first trimester (organogenesis), is associated with a risk of fetal harm, including specific congenital malformations such as aplasia cutis congenita and choanal atresia. The medicine is also excreted into breast milk.

There are formal safety-related restrictions: Mercazolil is restricted from use in individuals with a known history of acute pancreatitis following prior use of a thionamide derivative (carbimazole or thiamazole), due to the risk of recurrence.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Mercazolil (Thiamazole/Methimazole) describes overdosage by detailing expected manifestations and mandating specific emergency actions.

Documented Manifestations and Severe Outcomes: Acute manifestations officially listed include systemic effects such as fever, headache, and edema, alongside gastrointestinal signs like nausea, vomiting, and epigastric distress. The regulatory profile emphasizes the risk of severe, potentially delayed complications, including hematological disorders like agranulocytosis and aplastic anemia, as well as toxicity affecting the liver (hepatitis) and kidneys (nephrotic syndrome). Excessive or supratherapeutic exposure is also noted to potentially induce clinical signs of hypothyroidism.

Required Emergency Response: In the event of suspected overdosage, official guidance dictates that the individual contact a poison control center or emergency room at once. Immediate professional medical help must be sought if any life-threatening symptoms occur, specifically if the affected person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Management relies on appropriate symptomatic and supportive treatment, as no specific antidote is known for this compound.

Therapeutic Uses of Mercazolil

Mercazolil is used for the medical treatment of hyperthyroidism and is considered relevant when supportive symptom management is appropriate. The medication is commonly used across conditions presenting with acute episodes, such as Graves' disease or toxic multinodular goiter, to help establish and sustain a stable euthyroid state. This generally may assist with easing the overall symptom load associated with chronic endocrinological conditions.

The medication is generally applied to address symptom clusters that may become intense or disruptive, including cardiovascular overactivity like palpitations and rapid heartbeat, neurological symptoms such as tremor and anxiety, and symptoms related to systemic imbalance like heat intolerance. It is also relevant in contexts involving heightened systemic burden, such as Thyrotoxic crisis, and when supportive symptom management is appropriate during phases before a planned thyroidectomy or radioactive iodine therapy.


Quick Fact: Symptom Support in Neuro-Cardiovascular Domains
Mercazolil is relevant for easing symptoms related to heightened physiological activity, including pronounced symptoms of tremor and tachycardia associated with hyperthyroidism.

Regulatory References

  1. NIH DailyMed label for Methimazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Mercazolil?

Mercazolil (Thiamazole/Methimazole) eligibility is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations.


Eligibility Scope

Classification Population Regulatory Status
Allowed Adults and children aged 3 years and older Established use for hyperthyroidism.
Not Recommended Children under 2 years of age Safety and efficacy have not been systematically evaluated.
Restricted Pregnant women Conditional use only after strict individual benefit/risk assessment.
Contraindicated Nursing mothers Prohibited due to drug excretion into breast milk.

Absolute Contraindications

Use is prohibited in individuals with known hypersensitivity to the active substance or its components. It is also contraindicated in patients with severe hepatic insufficiency and those with serious pre-existing haematological conditions. Furthermore, treatment must be discontinued if conditions like agranulocytosis or severe liver abnormality emerge during therapy. Women of childbearing potential are required to use effective contraceptive measures while taking this medicine, as documented in official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Mercazolil (Thiamazole/Methimazole) based on changes in a patient's thyroid status and formal restrictions.


Documented Interaction Patterns

Interactions with Altered Clearance Due to Euthyroid State

The clearance rates of several co-administered medicines may be altered when a patient transitions from a hyperthyroid to a euthyroid state following Mercazolil treatment. Hyperthyroidism typically causes increased clearance of certain drugs, which then decreases upon successful treatment. This effect may result in increased serum levels of co-administered beta-adrenergic blocking agents, Digitalis glycosides, and Theophylline.

Pharmacodynamic and Procedural Interactions

Co-administration with oral anticoagulants (e.g., Warfarin) may lead to an altered effect on coagulation, potentially linked to an influence on Vitamin K activity. Additionally, Mercazolil is contraindicated for use in combination with Sodium Iodide I-131 (radioactive iodine) for therapeutic purposes because it reduces the radioisotope's efficacy. Anti-thyroid therapy must be discontinued 3 to 4 days before the administration of radioiodide. Regulatory labeling also includes a specific caution regarding co-administration with other drugs known to cause agranulocytosis.

Mechanism of Action

Mercazolil is a synthetic compound that exerts its primary mechanism of action through the inhibition of the Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling pathway and modulation of the hypothalamic-pituitary-adrenal (HPA) axis.

Primary Pathway Inhibition

This pathway inhibition blocks the activation of transcription factors involved in the immune response. Specifically, this action causes a reduction in the synthesis of pro-inflammatory mediators, such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha), which limits the propagation of signaling cascades that initiate cellular inflammation. This mechanism directly disrupts the intracellular processes that drive systemic immune responses.

Receptor Modulation and Downstream Effects

Additionally, Mercazolil modulates gene expression by increasing the density and sensitivity of anti-inflammatory glucocorticoid receptors (GRs) in peripheral tissues. The enhanced signaling through the GRs promotes the transcription of anti-inflammatory proteins, while concurrently suppressing the activity of pro-inflammatory transcription factors (e.g., NF-kappaB), thereby contributing to the overall system-level modulation of inflammatory homeostasis.

Dosage and Administration Information

How Mercazolil is Used: Official Administration Guidelines

Mercazolil (Thiamazole/Methimazole) is an oral antithyroid medication. This section details the official instructions for administration and dosing.


Administration and Dosage Regimen

Feature Official Instructions
Route and Form Administered orally as a fixed-dose tablet (5 mg and 10 mg strengths).
Initial Adult Dosing Varies by severity: Typically mathbf15 mg to mathbf60 mg total daily dose.
Dosing Frequency (Initial) The initial daily dosage is usually given in 3 divided doses at approximately mathbf8 -hour intervals to establish control.
Maintenance Adult Dosing mathbf5 mg to mathbf15 mg total daily dose, often administered once daily.

Use Over Time and Population Rules

Mercazolil treatment involves two distinct phases. The initial, higher, divided-dose phase continues until the patient achieves a euthyroid (normal) state. The dose is then officially reduced to the lower maintenance dose range to sustain this stable condition. A rising Thyroid-Stimulating Hormone (TSH) level may indicate the need for a further dose reduction.

For pediatric patients, the initial dosage is based on body weight, starting at approximately mathbf0.4 mg/kg of body weight daily, also given in divided doses. As an oral tablet, no dilution or preparation is required prior to administration.

Recent Clinical Evidence

Evidence for Use in Managing Graves' Disease

The research base for Mercazolil in Graves' disease relies heavily on numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Researchers primarily focused on measuring the time required to normalize levels of thyroid hormones (T3, T4)—a state known as euthyroidism—and the proportion of patients who maintain this state after the medication is stopped (known as remission). Studies also monitored outcomes related to symptoms, such as rapid heart rate, that were observed in the populations during the study period.

Studies reported measurements related to remission, which showed significant variability across different groups and geographical regions. Research also tracked the recurrence of hyperthyroidism (relapse), which was a common pattern observed in the years after the medication was stopped. Results for the rate of remission often appear mixed, indicating that research is ongoing to define the duration that was explored.


Evidence for Use in Treating Toxic Multinodular Goiter

For the management of toxic multinodular goiter (TMNG), the evidence largely stems from long-term clinical trials and observational cohort studies that follow patients over extended time intervals. Research examined how thyroid function levels are maintained over many years, as well as the changes in goiter size in populations not electing for definitive therapy. These studies monitor outcomes related to systemic imbalance under conditions characterized by fluctuating manifestations.


Long-Term Study Findings and Durability of Control

Research has explored the durability of thyroid function control over defined time intervals. Findings describe the proportion of patients who experience a relapse of hyperthyroidism after stopping therapy, which is often observed in the first few years after discontinuation. A significant research limitation is that even the longest follow-up durations available only cover a segment of a person's life, meaning that the full lifelong pattern and the ultimate permanence of remission are not fully established.


Current Gaps in the Research Evidence

The existing body of research highlights several key areas where certainty remains low or data are still emerging. There is limited information for long-term outcomes in very specific subgroups, such as the frail older adult population. Research is ongoing to fully describe how the medication may influence the underlying autoimmune process that drives Graves' disease.

Key Studies & References

  1. Methimazole Tablets, USP (DailyMed - Official FDA Labeling)
  2. Methimazole - StatPearls (NCBI Bookshelf)
  3. Methimazole - eEML (WHO Electronic Essential Medicines List)

Frequently Asked Questions (FAQ)

Common questions about Mercazolil (FAQ)


Q: What happens if I miss a dose of Mercazolil—should I take it late or skip it?

Official patient information often describes a general principle: if a dose is missed, one may take it as soon as it is remembered. However, if it is already almost time for the next scheduled dose, the information suggests skipping the missed dose and returning to the regular schedule. The guidance specifies that a double dose should not be taken to compensate for the missed one.


Q: Does Mercazolil cause weight gain, or is that a misunderstanding?

Weight gain is listed in official regulatory labeling as a potential symptom of hypothyroidism (low thyroid hormone levels), which can be a possible side effect of Mercazolil therapy. The primary goal of the medication is to maintain normal thyroid levels. Changes in weight may be monitored by a healthcare professional as they may indicate a need for further evaluation.


Q: Are there any specific foods or drinks I need to avoid while on Mercazolil?

No known interactions with specific foods or drinks are listed in the official regulatory product information for Mercazolil. The official label does not mandate taking the medication with food, but it may be taken with food if recommended by a healthcare provider for relief of common side effects like stomach upset.


Q: Can taking Mercazolil affect my sleep patterns or cause insomnia?

Insomnia is not explicitly listed among the most common adverse effects in official documents, though the product labeling does report other central nervous system effects such as drowsiness (sleepiness) and dizziness. Patients are generally advised to discuss any new or worsening symptoms, including changes in sleep, with their healthcare provider.


Q: Why do some people experience a metallic taste in their mouth with Mercazolil?

The official product labeling for Mercazolil includes a change in taste or a decreased sense of taste as a reported side effect. This change is considered an adverse effect that is documented in product information.


Q: Is it safe to drive or operate machinery while taking Mercazolil?

Regulatory documents list side effects such as dizziness and drowsiness that may affect one's ability to concentrate or perform skilled tasks. Due to the potential for these side effects, patients are advised to assess their individual response to the medication before engaging in activities that require full attention, like driving or operating machinery.


Q: Does the time of day I take Mercazolil matter for its effectiveness?

For the drug to work best, it is important to maintain consistent blood levels. Official guidance for the initial, divided-dose phase generally specifies that doses should be taken at evenly spaced times throughout the day. If one is on a once-daily maintenance dose, taking it at the same time each day helps maintain this consistency.


Q: Can Mercazolil cause stomach upset or nausea when first starting the medicine?

Yes, nausea, vomiting, and general stomach upset (epigastric distress) are listed in official adverse reaction reports as common side effects of Mercazolil. While these symptoms are common, patients should report them to their healthcare provider as they may require professional assessment.


Q: What is the connection between Mercazolil and immune system effects?

Mercazolil is known to cause rare, but serious, immune-related side effects, which are documented in the official safety profile. These include agranulocytosis (a severe drop in infection-fighting white blood cells) and ANCA-positive vasculitis (inflammation of blood vessels), underscoring the need for careful medical monitoring.


Q: What should I do if I develop a rash after starting Mercazolil?

The official label specifies that any evidence of illness, including a skin eruption (rash), should be reported to the patient's healthcare professional. A skin reaction is an adverse effect that warrants medical consultation, as it may require evaluation to determine its severity.


Q: Does Mercazolil interact with herbal remedies or supplements like St. John's Wort?

Official product information emphasizes that a healthcare professional should be informed about all current medicines and supplements, including herbal products. This is because interactions, even with supplements, can potentially alter Mercazolil's therapeutic effects or increase the risk of certain side effects.


Q: Is there a link between Mercazolil and changes in taste or smell?

Yes, regulatory documents list decreased sense of taste or a change in taste as a reported adverse reaction. Changes in taste or smell are documented as reported adverse reactions to the medication.


Q: Why do people sometimes need to take a thyroid hormone replacement alongside Mercazolil?

Mercazolil works by reducing thyroid hormone production, and treatment can sometimes lead to hypothyroidism (low thyroid levels). Regulatory labeling indicates that the use of thyroid hormone replacement may be needed in such cases to maintain stable hormone levels and prevent symptoms associated with low thyroid function.


Q: Is there any research on Mercazolil's effectiveness in children or adolescents?

Yes, Mercazolil is approved for use in pediatric patients aged 3 years and older. Official regulatory documents indicate that appropriate studies have been conducted to establish its safety and effectiveness for treating hyperthyroidism in this specific population.

How should Mercazolil be stored and disposed of?

How to Store and Dispose of Methimazole (Mercazolil)

Methimazole tablets must be stored at Controlled Room Temperature (CRT), maintaining a specific range between 20 and 25 C (68 to 77 F).


Storage and Protection

The medication must be kept in a tight, light-resistant container, and the container must remain tightly closed to ensure stability. Consistent with safety requirements for all pharmaceuticals, methimazole must be stored out of the sight and reach of children.

Disposal Instructions

The preferred method for discarding unused or expired methimazole is through an official drug take-back program. Because the product is not authorized for disposal via household drains, if a take-back program is unavailable, the tablets must be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mercazolil found in:

A-Z Index: